The global anti-obesity medication market accounted for USD 6.64 billion in 2023 and is expected to reach at USD 137.40 billion by 2034 with a CAGR of 31.71% during the forecast period 2024-2034. The market will grow as a result of factors such as the growing geriatric population, growing public awareness and concern about weight management, the rising prevalence of obesity and related chronic diseases, and strategic collaborations and partnerships.
The growing incidence of obesity globally is one of the main factors propelling the market for anti-obesity medications. Urbanization, bad eating patterns, and sedentary lifestyles are some of the factors that are contributing to the rising rate of obesity in all age categories. The market is growing as a result of the rising need for pharmaceutical therapies that help address obesity trends. For instance, Boehringer Ingelheim International GmbH announced in January 2024 the establishment of a new research alliance aimed at finding and creating innovative treatments for obesity and associated metabolic disorders.
By product, the approved product segment accounted for the highest revenue-grossing segment in the global anti-obesity medication market in 2023 and is predicted to grow at the fastest CAGR during the forecast period owing to the high efficacy, established safety profile, and widespread availability of approved anti-obesity medications, driving increased adoption and market penetration. For instance, Boehringer Ingelheim's decision to proceed with survodutide into Phase III trials in August 2023 indicates the increased interest in novel medicines. Phase II evidence demonstrating up to 19% weight loss highlights the potential efficacy of such drugs.
By the mechanism of action, the peripherally acting anti-obesity drugs segment accounted for the highest revenue-grossing segment in the global anti-obesity medication market in 2023 owing to the irreversible inhibition of pancreatic lipase, leading to reduced absorption of dietary fats and enhanced weight loss outcomes, thereby driving significant revenue growth in the segment. For instance, Vivus, Inc. announced in October 2023 that it would be working with a new partner to develop and market Qsymia (phentermine/topiramate) in a particular area. Additionally, the centrally acting drugs segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased understanding of the central nervous system's role in regulating appetite and metabolism, leading to the development of novel centrally acting drugs with improved efficacy and safety profiles, driving robust growth in the segment.
By distribution channel, the retail pharmacies segment accounted for the highest revenue-grossing segment in the global anti-obesity medication market in 2023 owing to the convenience, accessibility, and wide distribution network of retail pharmacies, catering to the growing demand for anti-obesity medications among consumers seeking over-the-counter and prescription options. For instance, in December 2023, Roche announced the acquisition of Carmot Therapeutics for USD 2.7 billion plus up to USD 400 million in milestones, acquiring access to clinical-stage obesity treatments, including lead asset CT-388, which targets obesity and related illnesses. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing preference for online shopping, the convenience of home delivery, and expanding digital infrastructure, facilitating easy access to a wide range of anti-obesity medications and driving significant growth in the segment.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of obesity, well-established healthcare infrastructure, increasing adoption of anti-obesity medications, and robust research and development activities, driving substantial revenue growth in the North American region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness about obesity-related health risks, improving healthcare infrastructure, increasing disposable incomes, and growing prevalence of obesity in emerging economies, driving significant market expansion in the Asia Pacific region. For instance, Novo Nordisk's November 2023 investment in expanding production facilities in Chartres, France, demonstrates confidence in the market's potential. The investment, which exceeds USD 2.32 billion, would increase capacity for chronic disease treatments, including anti-obesity drugs.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
The growing incidence of obesity globally is one of the main factors propelling the market for anti-obesity medications. Urbanization, bad eating patterns, and sedentary lifestyles are some of the factors that are contributing to the rising rate of obesity in all age categories. The market is growing as a result of the rising need for pharmaceutical therapies that help address obesity trends. For instance, Boehringer Ingelheim International GmbH announced in January 2024 the establishment of a new research alliance aimed at finding and creating innovative treatments for obesity and associated metabolic disorders.
By product, the approved product segment accounted for the highest revenue-grossing segment in the global anti-obesity medication market in 2023 and is predicted to grow at the fastest CAGR during the forecast period owing to the high efficacy, established safety profile, and widespread availability of approved anti-obesity medications, driving increased adoption and market penetration. For instance, Boehringer Ingelheim's decision to proceed with survodutide into Phase III trials in August 2023 indicates the increased interest in novel medicines. Phase II evidence demonstrating up to 19% weight loss highlights the potential efficacy of such drugs.
By the mechanism of action, the peripherally acting anti-obesity drugs segment accounted for the highest revenue-grossing segment in the global anti-obesity medication market in 2023 owing to the irreversible inhibition of pancreatic lipase, leading to reduced absorption of dietary fats and enhanced weight loss outcomes, thereby driving significant revenue growth in the segment. For instance, Vivus, Inc. announced in October 2023 that it would be working with a new partner to develop and market Qsymia (phentermine/topiramate) in a particular area. Additionally, the centrally acting drugs segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased understanding of the central nervous system's role in regulating appetite and metabolism, leading to the development of novel centrally acting drugs with improved efficacy and safety profiles, driving robust growth in the segment.
By distribution channel, the retail pharmacies segment accounted for the highest revenue-grossing segment in the global anti-obesity medication market in 2023 owing to the convenience, accessibility, and wide distribution network of retail pharmacies, catering to the growing demand for anti-obesity medications among consumers seeking over-the-counter and prescription options. For instance, in December 2023, Roche announced the acquisition of Carmot Therapeutics for USD 2.7 billion plus up to USD 400 million in milestones, acquiring access to clinical-stage obesity treatments, including lead asset CT-388, which targets obesity and related illnesses. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing preference for online shopping, the convenience of home delivery, and expanding digital infrastructure, facilitating easy access to a wide range of anti-obesity medications and driving significant growth in the segment.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of obesity, well-established healthcare infrastructure, increasing adoption of anti-obesity medications, and robust research and development activities, driving substantial revenue growth in the North American region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness about obesity-related health risks, improving healthcare infrastructure, increasing disposable incomes, and growing prevalence of obesity in emerging economies, driving significant market expansion in the Asia Pacific region. For instance, Novo Nordisk's November 2023 investment in expanding production facilities in Chartres, France, demonstrates confidence in the market's potential. The investment, which exceeds USD 2.32 billion, would increase capacity for chronic disease treatments, including anti-obesity drugs.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Product, Mechanism of Action, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement. Click here for more details
Segmentation: Anti-obesity Medication Market Report 2023 - 2034
Anti-obesity Medication Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity)
- Topiramate (Dulaglutide (Trulicity))
- Others
Anti-obesity Medication Market Analysis & Forecast by Mechanism of Action 2023 - 2034 (Revenue USD Bn)
- Peripherally Acting Drugs
- Centrally Acting Drugs
Anti-obesity Medication Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Anti-obesity Medication Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)· North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Anti-obesity Medication Market: Product Estimates & Trend Analysis
8. Anti-obesity Medication Market: Mechanism of Action Estimates & Trend Analysis
9. Anti-obesity Medication Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Anti-obesity Medication Market
12. Europe Global Anti-obesity Medication Market
13. Asia Pacific Global Anti-obesity Medication Market
14. Latin America Global Anti-obesity Medication Market
15. MEA Global Anti-obesity Medication Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Novo Nordisk A/S
- Eisai Co. Ltd.
- Vivus Inc.
- Arena Pharmaceuticals Inc.
- Orexigen Therapeutics Inc.
- Nalpropion Pharmaceuticals Inc.
- Boehringer Ingelheim International GmbH
- Takeda Pharmaceutical Company Limited
- GlaxoSmithKline plc
- F. Hoffmann-La Roche Ltd
- Amgen Inc.
- Sanofi S.A.
- Pfizer Inc.
- Merck & Co. Inc.
- Johnson & Johnson Services Inc.
